Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.

@article{Freedman2012TeriflunomideAT,
  title={Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.},
  author={M. S. Freedman and Jerry S. Wolinsky and Barbara D. Wamil and Christian Confavreux and Giancarlo Comi and Ludwig Kappos and Tomas P. Olsson and Aaron Miller and Hadj Benzerdjeb and Hao Li and Catherine Simonson and P. W. O'Connor},
  journal={Neurology},
  year={2012},
  volume={78 23},
  pages={1877-85}
}
OBJECTIVE To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). METHODS A total of 118 patients with RMS were randomly assigned 1:1:1 to receive oral placebo or teriflunomide, 7 or 14 mg, once daily for 24 weeks; 86 patients entered the 24-week extension. The primary objective was to evaluate safety; secondary objectives were to evaluate the effects of treatment on disease activity assessed by MRI… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS